Home Southwest Austin, TX Direct Biologics COMPANY
Clinical Phase 3
3 open jobs · last seen Oct 23, 2026 · 10 sources
Profile checked Oct 10, 2026
Keywords: ARDS Inflammatory Bowel Diseases Covid19 COVID-19 Crohn Disease Perianal Fistula Crohn's Disease Perianal Fistula Due to Crohn's Disease Acute Respiratory Distress Syndrome Ulcerative Colitis Hypoxia Cytokine Storm Postviral Syndrome Dyspnea Human ARDS Solid Organ Transplant Rejection Organ Rejection Transplants Organ Rejection ExoFlo DB-3Q Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Show all 21 keywords
Hiring Title Location (from posting) Employer posted First seen Senior Accountant Austin, Texas, United States Oct 16, 2026 Oct 17, 2026 Director, Data Management Austin, Texas, United States Sep 22, 2026 Oct 11, 2026 Scientist, Process Sciences - Analytical Development Poway, California, United States Sep 15, 2026 Oct 11, 2026
See all 3 jobs
At a glance HQ Austin, TX source Region Southwest Stage Clinical Phase 3 Latest trial Phase 2: DB-3Q for the Treatment of Medically Refractory Crohn's Disease (Jun 1, 2026) source Timeline Jun 1, 2026 Trial start Phase 2: DB-3Q for the Treatment of Medically Refractory Crohn's Disease source ↗ May 19, 2025 Trial start Phase 2: DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease source ↗ 2024-12 Trial start Phase 1/Phase 2: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS source ↗ 2024-11 Trial start Phase 1/Phase 2: ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome source ↗ Aug 28, 2023 Trial start Phase 1/Phase 2: Study of ExoFlo for the Treatment of Perianal Fistulas source ↗ Jan 23, 2023 Trial start Phase 1: Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease source ↗ Dec 19, 2022 Trial start Phase 1: Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis source ↗ Dec 7, 2022 Trial start Phase 2: Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19 source ↗ Jul 1, 2022 Trial start Phase 3: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) source ↗ Sep 24, 2020 Trial start Phase 2: Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS source ↗ Upcoming milestones 2027-06 (ESTIMATED) · Phase 2 · DB-3Q for the Treatment of Medically Refractory Crohn's Disease · NCT07625293 Jul 30, 2027 (ESTIMATED) · Phase 2 · DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease · NCT06918808 Nov 30, 2027 (ESTIMATED) · Phase 3 · Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) · NCT05354141 Estimated primary completion per ClinicalTrials.gov. Dates move.
Clinical trials (lead sponsor) 12 Record Title Phase Status Start Primary completion NCT07625293 DB-3Q for the Treatment of Medically Refractory Crohn's Disease Phase 2 Recruiting Jun 1, 2026 2027-06 (estimated) NCT05836883 Study of ExoFlo for the Treatment of Perianal Fistulas Phase 1/Phase 2 Terminated Aug 28, 2023 Dec 1, 2024 (actual) NCT06918808 DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease Phase 2 Recruiting May 19, 2025 Jul 30, 2027 (estimated) NCT05354141 Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) Phase 3 Recruiting Jul 1, 2022 Nov 30, 2027 (estimated) NCT05130983 Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease Phase 1 Terminated Jan 23, 2023 Dec 1, 2024 (actual) NCT05176366 Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis Phase 1 Terminated Dec 19, 2022 Dec 1, 2024 (actual) NCT04657458 Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS Not listed No longer available Not listed Not listed NCT05116761 ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome Phase 1/Phase 2 Withdrawn 2024-11 2024-11 (estimated) NCT05127122 Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS Phase 1/Phase 2 Withdrawn 2024-12 2024-12 (estimated) NCT05215288 Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients Not listed No longer available Not listed Not listed NCT04493242 Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS Phase 2 Completed Sep 24, 2020 May 1, 2021 (actual) NCT05125562 Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19 Phase 2 Withdrawn Dec 7, 2022 Mar 7, 2023 (estimated)
Open jobs 3 Title Location (from posting, not HQ) Employer posted First seen Level Senior Accountant Austin, Texas, United States Oct 16, 2026 Oct 17, 2026 Not stated Director, Data Management Austin, Texas, United States Sep 22, 2026 Oct 11, 2026 Senior Description Scientist, Process Sciences - Analytical Development Poway, California, United States Sep 15, 2026 Oct 11, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Direct Biologics on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
